Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma

Summary

In this study patients with resectable basal cell carcinoma (BCC) who usually undergo surgery without prior anticancer treatment will be treated with antitumor medication. But since BCC is mainly localized in clearly visible regions of the body, as e.g. the face, there is also a need to reduce scars as a consequence of surgery which will be accomplished by neoadjuvant therapy. The used medication - vismodegib - displays controllable adverse events and shows a good efficacy for reduction of BCC lesions. It is expected that the neoadjuvant setting will lead to minor surgical intervention thus minimising surgical risks and scars for the patients.

Timeline

Start

2017-01

Primary completion

2020-01

Completion

2021-01

Publications

• Lauterbach B, Kakkassery V, Debus D, Heindl LM, Schultz ES. [Advanced periocular basal cell carcinoma-a therapeutic challenge]. Ophthalmologe. 2019 Mar;116(3):273-277. doi: 10.1007/s00347-018-0734-9. German.

Drugs

Indications